Back
Results - Announcements
Vivanza Biosciences Ltd consolidated sales up 46.07% on year in Q2FY2026
07-Aug-2026, 02:34
Vivanza Biosciences Ltd share price declined by 0.53% to Rs 1.89 after the company's net profit plunged by 133.33% to Rs 0.15 crore, while revenue from operations increased sharply by 46.07% to Rs 9.29 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.84 lakh crore, rising 5.32%. It has marginally improved by 0.53% over last one week and rose by 11.64% in last one month while the market capitalization of Vivanza Biosciences Ltd has inched up 2.72% and 0.53% in the same period respectively. Profit before tax (PBT) of Vivanza Biosciences Ltd stood at Rs 0.18 crore in Q2 FY26, rallying 100.00% year-on-year, and plunging by 160.00% quarter-on-quarter. EBITDA came in at Rs 0 crore, crashing by 438.46% YoY and expanding by 83.33% sequentially. Total expenses jumped by 41.75% to Rs 9.37 crore in Q2FY26 over Q2FY25. During the quarter, employee benefits expense was at Rs 0.1 crore, witnessing a strong rise of 42.86% YoY. For the TTM ended FY26, revenue from operations slumped by 73.35% to Rs 7.42 crore, while net profit tanked by 221.82% to Rs 0.67 crore, compared to previous TTM. EBITDA marginally improved 1% to Rs 0.43 crore, and PBT tumbled by 195.71% to Rs 0.67 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 2.5 crore in FY26, as against Rs 2.04 crore in FY25. Vivanza Biosciences Ltd nosedived by 9.57% in last one year, underperforming the benchmark BSE Sensex which has eased by 1.97% during the same period.
Vivanza Biosciences Ltd share price declined by 0.53% to Rs 1.89 after the company's net profit plunged by 133.33% to Rs 0.15 crore, while revenue from operations increased sharply by 46.07% to Rs 9.29 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.84 lakh crore, rising 5.32%. It has marginally improved by 0.53% over last one week and rose by 11.64% in last one month while the market capitalization of Vivanza Biosciences Ltd has inched up 2.72% and 0.53% in the same period respectively. Profit before tax (PBT) of Vivanza Biosciences Ltd stood at Rs 0.18 crore in Q2 FY26, rallying 100.00% year-on-year, and plunging by 160.00% quarter-on-quarter. EBITDA came in at Rs 0 crore, crashing by 438.46% YoY and expanding by 83.33% sequentially. Total expenses jumped by 41.75% to Rs 9.37 crore in Q2FY26 over Q2FY25. During the quarter, employee benefits expense was at Rs 0.1 crore, witnessing a strong rise of 42.86% YoY. For the TTM ended FY26, revenue from operations slumped by 73.35% to Rs 7.42 crore, while net profit tanked by 221.82% to Rs 0.67 crore, compared to previous TTM. EBITDA marginally improved 1% to Rs 0.43 crore, and PBT tumbled by 195.71% to Rs 0.67 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 2.5 crore in FY26, as against Rs 2.04 crore in FY25. Vivanza Biosciences Ltd nosedived by 9.57% in last one year, underperforming the benchmark BSE Sensex which has eased by 1.97% during the same period.